• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Sanofi (ADR)

NYSE:SNY

$34.31 $0.08 (0.23%)

REAL-TIME: Last trade at

Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet

Emerging Markets Exposure to Europe

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

Sachs Associates to host a forum

Generic Versions of Plavix Get FDA Approval

Dr. Reddy's Labs announces the launch of Clopidogrel tablets, USP

Mylan (MYL) Unit Launches Generic Version of Sanofi-Aventis' (SNY) Plavix

Plavix about to lose patent protection, NYT says

Global Human Vaccines Industry

Big Changes to Buffett and Berkshire Hathaway Stock Holdings, A to Z

Amylin climbs after report says seven companies involved in sales process

Amylin takeover could get done in mid-$30's per share, says Leerink

Amylin draws interest from Pfizer, AstraZeneca, Sanofi, Bloomberg reports

Short Sellers Cast a Wide Net (ACI, XCO, SD, FST, XOM, DUK, AMD, SNY, PFE, NOK, BKS, SVU, PBI, DV, BPI)

BioNJ to host a conference

Sony’s Turnaround Dreams

Sanofi initiated with a Buy at Societe Generale

Vertex Is the Next Gilead Sciences or Alexion

The FDA Pediatric Advisory Committee to hold a meeting

Top Metals and Mining Stocks Gained 27% (VAN,VAN:BRU,SNY)

Genzyme gets regulatory approvals of expanded waterford, Ireland plant

Dow at 4-Year High: Buy, Sell or Hold?

Pfizer is Still a Pharmaceutical-Giant Buy

Sanofi announces Phase III data for QIV

Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine

Sanofi-Aventis Sees A Bright Future In Boston-Cambridge

Sanofi-Aventis's CEO Discusses Q1 2012 Results - Earnings Call Transcript

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

Leerink's biotech analysts hold an analyst/industry conference call

Sanofi says Q1 performance in line with FY12 guidance

Sanofi: Strong performance in Q1 2012 including Genzyme contribution

Sanofi declines to comment on potential interest in Amylin, Bloomberg reports

Sanofi Profit Rises On Genzyme Buy, Lantus Strength

Sanofi CFO Jérôme Contamine Comments on Q1 2012 Results

Sanofi-aventis, U.S., LLC; Withdrawal of Approval of a New Drug Application for OFORTA

Glaxo Plays Hardball With Human Genome Sciences (GSK, HGSI, SNY, NVS)

Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif® in Phase III Trial

The Healthcare Packaging Market 2012-2022

Critical Alerts For Wells Fargo, Sanofi Aventis, Delta, InterActiveCorp, and DeVry Released By InvestorsObserver

Critical Alerts For Wells Fargo, Sanofi Aventis, Delta, InterActiveCorp, and DeVry Released By InvestorsObserver

See More Articles...